Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
10%(1 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_4
8
47%
Ph not_applicable
4
24%
Ph phase_2
2
12%
Ph phase_3
3
18%

Phase Distribution

0

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution17 total trials
Phase 2Efficacy & side effects
2(11.8%)
Phase 3Large-scale testing
3(17.6%)
Phase 4Post-market surveillance
8(47.1%)
N/ANon-phased studies
4(23.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Active(1)
Completed(10)
Terminated(2)
Other(4)

Detailed Status

Completed10
unknown4
Withdrawn1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (11.8%)
Phase 33 (17.6%)
Phase 48 (47.1%)
N/A4 (23.5%)

Trials by Status

unknown424%
withdrawn16%
completed1059%
not_yet_recruiting16%
terminated16%

Recent Activity

0 active trials
Showing 5 of 17
completedphase_4

Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy

NCT03210688
not_yet_recruitingphase_4

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

NCT06272227
completedphase_2

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

NCT02824718
completedphase_4

Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

NCT03147677
unknownphase_4

Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly

NCT03292744
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT03210688Phase 4

Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy

Completed
NCT06272227Phase 4

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

Not Yet Recruiting
NCT02824718Phase 2

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

Completed
NCT03147677Phase 4

Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Completed
NCT03292744Phase 4

Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly

Unknown
NCT02895061Not Applicable

Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.

Completed
NCT01774812Phase 2

Vitamin D and Cardiac Autonomic Tone in Hemodialysis

Completed
NCT02747381Phase 4

The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients

Completed
NCT02327091Phase 3

The Effect of Alfacalcidol on Muscle Strength in Elderly Indonesian Women : A Randomized Controlled Trial

Completed
NCT01974167Not Applicable

Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

Unknown
NCT00165698Phase 3

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

Completed
NCT00144456Phase 3

A New Active Vitamin D, ED-71 for Osteoporosis

Completed
NCT01765010Phase 4

The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels

Unknown
NCT01752244Not Applicable

Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects

Unknown
NCT00483275Phase 4

Fall Prevention by Alfacalcidol and Training

Withdrawn
NCT00469599Not Applicable

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Terminated
NCT00168909Phase 4

Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17